Promise and Challenge : The Lens Model as a Biomarker for Early Diagnosis of Alzheimer's Disease

Abstract EN

Alzheimer’s disease (AD) is the most common form of dementia pathologically characterized by cerebral amyloid-beta (Aβ) deposition.

Early and accurate diagnosis of the disease still remains a big challenge.

There is evidence that Aβ aggregation starts to occur years before symptoms arise.

Noninvasive monitoring of Aβ plaques is critical for both the early diagnosis and prognosis of AD.

Presently, there is a major effort on looking for a reasonably priced technology capable of diagnosing AD by detecting the presence of Aβ.

Studies suggest that AD is systemic rather than brain-limited focus diseases and the aggregation of the disease-causing proteins also takes place in lens except the brain.

There is a possible relationship between AD and a specific subtype of age-related cataract (supranuclear cataract).

If similar abnormal protein deposits are present in the lens, it would facilitate non-invasive diagnosis and monitoring of disease progression.

However, there are controversies on the issues related to performance and validation of Aβ deposition in lens as biomarkers for early detection of AD.

Here we review the recent findings concerning Aβ deposition in the lenses of AD patients and evaluate if the ocular lens can provide a biomarker for AD.